IN VIVO’s Deals Of The Month: April 2016
Executive Summary
IN VIVO’s editors pick April's most significant deals, including DalCor Pharma's big B round and a rash of NASH deals. (Article free with registration.)
You may also be interested in...
Deal Watch: NASH In The Hot Seat
Regeneron stayed busy during the past two weeks, collaborating and making an equity commitment to CRISPR gene-editing biotech Intellia and signing an immuno-oncology deal with MedImmune. Allergan bounced off the termination of its merger with Pfizer by partnering with Heptares in neurological disease.
Tobira/Dong-A Partnership Will Add DPP-4 Inhibitor For NASH Combo Therapy
California biotech acquires rights to Suganon, approved for type 2 diabetes in South Korea, while partner Dong-A gets domestic rights to NASH candidate cenicriviroc.
Allergan's Back In The (M&A) Saddle Again Post-Pfizer Breakup
CEO Brent Saunders says company now is "recharged" and "ready to go," and it ends the day announcing a partnership wth Heptares.